PLRX Pliant Therapeutics Gross Profit Rate

PLRX (pliantrx.com) - company brandmark

FDA breakthrough therapy designation and a 100% patient retention rate in clinical trials create strong momentum for Pliant Therapeutics (PLRX). Marginal gross profit visualizes this optimism, where 0.00 reflects the baseline level of the metric. Prospects rely on the market launch of drugs targeting lung and liver fibrosis, although fierce competition with tech giants for leadership in this niche maintains risks.

Pliant Therapeutics, Inc. (PLRX): Gross Margin from 07/04/2022 to 11/20/2026

Analytical breakdowns and data insights for company Pliant Therapeutics Inc (PLRX)

- market value and analyst target forecast:
Fundamental valuation:PLRX - Pliant Therapeutics
Product sample of Pliant Therapeutics, Inc.

For Pliant Therapeutics (PLRX), which relies on external capacities for drug production, the gross margin reflects the efficiency of managing outsourcing costs relative to generated revenue. An analysis of gross margin profitability allows for an assessment of the revenue share remaining after direct production costs, which is critical for determining the business's capital intensity and avoiding overpayment for the asset during a strategic valuation.